ORAL (LD50): Acute: >2000 mg/kg Rat.
A hydroxylated metabolite of estradiol or estrone that has a hydroxyl group at C3-beta, 16-alpha, and 17-beta position. Estriol is a major urinary estrogen. During pregnancy, large amount of estriol is produced by the placenta. Isomers with inversion of the hydroxyl group or groups are called epiestriol. Though estriol is used as part of the primarily North American phenomenon of bioidentical hormone replacement therapy, it is not approved for use by the FDA or Health Canada. It is however available in the United States by prescription filled only by compounding pharmacies. It has also been approved and marketed throughout Europe and Asia for approximately 40 years for the treatment of post-menopausal hot flashes.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Prasterone | The risk or severity of adverse effects can be increased when Prasterone is combined with Estriol. |
| Exemestane | The therapeutic efficacy of Exemestane can be decreased when used in combination with Estriol. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estriol. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Estriol. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Estriol. |
| Lenalidomide | Estriol may increase the thrombogenic activities of Lenalidomide. |
| Ospemifene | The risk or severity of adverse effects can be increased when Estriol is combined with Ospemifene. |
| Ropinirole | Estriol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy. |
| Thalidomide | Estriol may increase the thrombogenic activities of Thalidomide. |
| Cetuximab | Estriol may increase the thrombogenic activities of Cetuximab. |
| Human immunoglobulin G | Estriol may increase the thrombogenic activities of Human immunoglobulin G. |
| Omalizumab | Estriol may increase the thrombogenic activities of Omalizumab. |
| Adalimumab | Estriol may increase the thrombogenic activities of Adalimumab. |
| Gemtuzumab ozogamicin | Estriol may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Indium In-111 satumomab pendetide | Estriol may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Infliximab | Estriol may increase the thrombogenic activities of Infliximab. |
| Trastuzumab | Estriol may increase the thrombogenic activities of Trastuzumab. |
| Rituximab | Estriol may increase the thrombogenic activities of Rituximab. |
| Basiliximab | Estriol may increase the thrombogenic activities of Basiliximab. |
| Muromonab | Estriol may increase the thrombogenic activities of Muromonab. |
| Digoxin Immune Fab (Ovine) | Estriol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Ibritumomab tiuxetan | Estriol may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Tositumomab | Estriol may increase the thrombogenic activities of Tositumomab. |
| Alemtuzumab | Estriol may increase the thrombogenic activities of Alemtuzumab. |
| Capromab pendetide | Estriol may increase the thrombogenic activities of Capromab pendetide. |
| Efalizumab | Estriol may increase the thrombogenic activities of Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | Estriol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit). |
| Natalizumab | Estriol may increase the thrombogenic activities of Natalizumab. |
| Palivizumab | Estriol may increase the thrombogenic activities of Palivizumab. |
| Daclizumab | Estriol may increase the thrombogenic activities of Daclizumab. |
| Bevacizumab | Estriol may increase the thrombogenic activities of Bevacizumab. |
| Technetium Tc-99m arcitumomab | Estriol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Eculizumab | Estriol may increase the thrombogenic activities of Eculizumab. |
| Panitumumab | Estriol may increase the thrombogenic activities of Panitumumab. |
| Ranibizumab | Estriol may increase the thrombogenic activities of Ranibizumab. |
| Galiximab | Estriol may increase the thrombogenic activities of Galiximab. |
| Pexelizumab | Estriol may increase the thrombogenic activities of Pexelizumab. |
| Afelimomab | Estriol may increase the thrombogenic activities of Afelimomab. |
| Epratuzumab | Estriol may increase the thrombogenic activities of Epratuzumab. |
| Bectumomab | Estriol may increase the thrombogenic activities of Bectumomab. |
| Oregovomab | Estriol may increase the thrombogenic activities of Oregovomab. |
| IGN311 | Estriol may increase the thrombogenic activities of IGN311. |
| Adecatumumab | Estriol may increase the thrombogenic activities of Adecatumumab. |
| Labetuzumab | Estriol may increase the thrombogenic activities of Labetuzumab. |
| Matuzumab | Estriol may increase the thrombogenic activities of Matuzumab. |
| Fontolizumab | Estriol may increase the thrombogenic activities of Fontolizumab. |
| Bavituximab | Estriol may increase the thrombogenic activities of Bavituximab. |
| CR002 | Estriol may increase the thrombogenic activities of CR002. |
| Rozrolimupab | Estriol may increase the thrombogenic activities of Rozrolimupab. |
| Girentuximab | Estriol may increase the thrombogenic activities of Girentuximab. |
| Obiltoxaximab | Estriol may increase the thrombogenic activities of Obiltoxaximab. |
| XTL-001 | Estriol may increase the thrombogenic activities of XTL-001. |
| NAV 1800 | Estriol may increase the thrombogenic activities of NAV 1800. |
| Briakinumab | Estriol may increase the thrombogenic activities of Briakinumab. |
| Otelixizumab | Estriol may increase the thrombogenic activities of Otelixizumab. |
| AMG 108 | Estriol may increase the thrombogenic activities of AMG 108. |
| Iratumumab | Estriol may increase the thrombogenic activities of Iratumumab. |
| Enokizumab | Estriol may increase the thrombogenic activities of Enokizumab. |
| Ramucirumab | Estriol may increase the thrombogenic activities of Ramucirumab. |
| Farletuzumab | Estriol may increase the thrombogenic activities of Farletuzumab. |
| Veltuzumab | Estriol may increase the thrombogenic activities of Veltuzumab. |
| Ustekinumab | Estriol may increase the thrombogenic activities of Ustekinumab. |
| PRO-542 | Estriol may increase the thrombogenic activities of PRO-542. |
| TNX-901 | Estriol may increase the thrombogenic activities of TNX-901. |
| RI 624 | Estriol may increase the thrombogenic activities of RI 624. |
| Stamulumab | Estriol may increase the thrombogenic activities of MYO-029. |
| CT-011 | Estriol may increase the thrombogenic activities of CT-011. |
| Leronlimab | Estriol may increase the thrombogenic activities of Leronlimab. |
| Glembatumumab vedotin | Estriol may increase the thrombogenic activities of Glembatumumab vedotin. |
| Olaratumab | Estriol may increase the thrombogenic activities of Olaratumab. |
| IPH 2101 | Estriol may increase the thrombogenic activities of IPH 2101. |
| TB-402 | Estriol may increase the thrombogenic activities of TB-402. |
| Caplacizumab | Estriol may increase the thrombogenic activities of Caplacizumab. |
| IMC-1C11 | Estriol may increase the thrombogenic activities of IMC-1C11. |
| Eldelumab | Estriol may increase the thrombogenic activities of Eldelumab. |
| Lumiliximab | Estriol may increase the thrombogenic activities of Lumiliximab. |
| Canakinumab | Estriol may increase the thrombogenic activities of Canakinumab. |
| Ipilimumab | Estriol may increase the thrombogenic activities of Ipilimumab. |
| Nimotuzumab | Estriol may increase the thrombogenic activities of Nimotuzumab. |
| Clenoliximab | Estriol may increase the thrombogenic activities of Clenoliximab. |
| Tocilizumab | Estriol may increase the thrombogenic activities of Tocilizumab. |
| BIIB015 | Estriol may increase the thrombogenic activities of BIIB015. |
| Sonepcizumab | Estriol may increase the thrombogenic activities of Sonepcizumab. |
| Motavizumab | Estriol may increase the thrombogenic activities of Motavizumab. |
| Elotuzumab | Estriol may increase the thrombogenic activities of Elotuzumab. |
| AVE9633 | Estriol may increase the thrombogenic activities of AVE9633. |
| Carotuximab | Estriol may increase the thrombogenic activities of Carotuximab. |
| XmAb 2513 | Estriol may increase the thrombogenic activities of XmAb 2513. |
| Coltuximab ravtansine | Estriol may increase the thrombogenic activities of Coltuximab ravtansine. |
| Lucatumumab | Estriol may increase the thrombogenic activities of Lucatumumab. |
| Pertuzumab | Estriol may increase the thrombogenic activities of Pertuzumab. |
| Siplizumab | Estriol may increase the thrombogenic activities of Siplizumab. |
| Apolizumab | Estriol may increase the thrombogenic activities of Apolizumab. |
| Sibrotuzumab | Estriol may increase the thrombogenic activities of Sibrotuzumab. |
| Bivatuzumab | Estriol may increase the thrombogenic activities of Bivatuzumab. |
| Lerdelimumab | Estriol may increase the thrombogenic activities of Lerdelimumab. |
| Lexatumumab | Estriol may increase the thrombogenic activities of Lexatumumab. |
| Reslizumab | Estriol may increase the thrombogenic activities of Reslizumab. |
| Teplizumab | Estriol may increase the thrombogenic activities of Teplizumab. |
| Catumaxomab | Estriol may increase the thrombogenic activities of Catumaxomab. |